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Role of Gonococcal Neisserial Surface Protein A (NspA) in
Serum Resistance and Comparison of Its Factor H Binding
Properties with Those of Its Meningococcal Counterpart
Lisa A. Lewis,a Peter A. Rice,a Sanjay Rama
aDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
ABSTRACT Neisseria gonorrhoeae, the causative agent of gonorrhea, has evolved
several mechanisms to subvert complement, including binding of the complement
inhibitor factor H (FH). We previously reported FH binding to N. gonorrhoeae inde-
pendently of lipooligosaccharide (LOS) sialylation. Here we report that factor H-like
protein 1 (FHL-1), which contains FH domains 1 through 7 and possesses
complement-inhibitory activity, also binds to N. gonorrhoeae. The ligand for both FH
and FHL-1 was identified as neisserial surface protein A (NspA), which has previously
been identified as a ligand for these molecules on Neisseria meningitidis. As with N.
meningitidis NspA (Nm-NspA), N. gonorrhoeae NspA (Ng-NspA) bound FH/FHL-1
through FH domains 6 and 7. Binding of FH/FHL-1 to NspA was human specific; the
histidine (H) at position 337 of domain 6 contributed to human-specific FH binding
to both Ng- and Nm-NspA. FH/FHL-1 bound Nm-NspA better than Ng-NspA; intro-
ducing Q at position 73 (loop 2, present in Ng-NspA) or replacing V and D at posi-
tions 112 and 113 in Nm-NspA loop 3 with A and H (Ng-NspA), respectively, reduced
FH/FHL-1 binding. The converse Ng-NspA to Nm-NspA mutations increased FH/FHL-1
binding. Binding of FH/FHL-1 through domains 6 and 7 to N. gonorrhoeae increased
with truncation of the heptose I (HepI) chain of LOS and decreased with LOS sialyla-
tion. Loss of NspA significantly decreased serum resistance of N. gonorrhoeae with
either wild-type or truncated LOS. This report highlights the role for NspA in en-
abling N. gonorrhoeae to subvert complement despite LOS phase variation. Knowl-
edge of FH-NspA interactions will inform the design of vaccines and immunothera-
pies against the global threat of multidrug-resistant gonorrhea.
KEYWORDS factor H, Neisseria, NspA, complement
Neisseria gonorrhoeae is responsible for about 80 million cases of the sexuallytransmitted disease gonorrhea worldwide each year (1). There were 468,514 cases
(145.8 gonorrhea cases per 100,000 population) reported in the United States in 2016,
which represents a 46% increase from the number of reported cases in 2011 (2). The
true incidence of disease is estimated to be about twice the reported incidence due to
underreporting and because a number of infections go undiagnosed each year (3, 4).
Undiagnosed infections further complicate effective control of this disease. N. gonor-
rhoeae infection of women can result in pelvic inflammatory disease, salpingitis, and
loss of fertility. Effective vaccines to prevent the spread of N. gonorrhoeae are not
available, and the bacterium is rapidly becoming untreatable with existing antibiotics
(5–9). The growing reality of the threat of untreatable N. gonorrhoeae infection has
ushered in an era where the discovery of new therapeutics and effective vaccines to
thwart the unchecked spread of this disease is urgently needed (10).
Vaccines that protect against infection with Neisseria meningitidis are available.
Several of these vaccines target meningococcal polysaccharide capsules and thus
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would not be effective against infection with N. gonorrhoeae. However, effective
meningococcal vaccines that target the factor H binding protein (fHbp) and/or other
surface proteins of N. meningitidis have also been developed (11–13); a recent study
suggests that one such vaccine may also provide limited protection against gonococcal
infection (14). Immunization with fHbp, for example, elicits serum bactericidal antibod-
ies that protect against meningococcal infection. An added advantage of anti-fHbp
vaccine antibodies may be their ability to block binding of the complement inhibitor
human factor H (FH) to fHbp, thereby interrupting an important mechanism of immune
evasion used by meningococci (15, 16).
FH regulates alternative complement pathway (AP) activation by acting as a cofactor
for factor I-mediated cleavage of C3b to iC3b (cofactor activity) and also serves to
irreversibly dissociate Bb from the AP C3 convertase C3b,Bb (decay-accelerating activ-
ity). FH is a 150-kDa glycoprotein that consists of 20 repetitive short consensus repeats
(SCRs) that resemble beads on a string; each SCR is 60 amino acids and forms a
globular structure (17, 18). Although similar in structure, the SCR domains exhibit
different activities. Only SCRs 1 to 4 possess complement-inhibitory activities (19–21),
while SCRs 7 and 20 bind polyanions such as heparin (22, 23). FH assists with discrim-
ination of self from nonself by binding to host glycosaminoglycans (GAGs) and pre-
venting unwanted complement attack (24).
FH-like protein 1 (FHL-1) is an alternatively spliced variant of FH that contains the
seven N-terminal SCRs of FH with the distinction that the C-terminal SCR (SCR7) is
differentially spliced and encodes four unique C-terminal amino acids (SFTL) (20, 25).
FHL-1 retains all the regulatory functions of FH, which include cofactor activity for the
factor I-mediated cleavage of C3b and accelerating the decay of alternative pathway
C3/C5 convertases (26). Similar to FH (27), FHL-1 also binds select GAGs through SCR7
(28). In human blood, the concentration of FH is 500 g/ml, and that of FHL-1 is
50 g/ml, resulting in an FH/FHL-1 molar ratio of approximately 3:1 (28–30). The role
of FHL-1 in AP regulation is often overlooked; however, FHL-1 has been identified
recently as the main regulatory protein in the extracellular matrix underlying the
human retina, called Bruch’s membrane (28).
Pathogenic bacteria, including N. meningitidis and N. gonorrhoeae, have evolved
mechanisms to hijack host complement-regulatory molecules and protect themselves
against unwanted complement activation (31). Both N. gonorrhoeae and N. meningitidis
bind the complement regulator FH to evade killing by the innate immune system
(32–39). Meningococcal fHbp and NspA proteins bind to FH SCR6 and -7 (32, 40). In
addition, some N. meningitidis PorB types bind directly to FH SCR6 and -7 (34). Several
other microbes also bind to FH SCR domains 6 and 7 (reviewed in reference 39). FHL-1,
like FH, binds to the same microbial ligands that interact with FH SCR6 and -7. In
contrast, N. gonorrhoeae strains bind FH SCRs 18 to 20 when they are grown in medium
that enables lipooligosaccharide (LOS) sialylation (36, 37, 41); binding of FH to sialylated
gonococci also requires N. gonorrhoeae porin (42). Sialic acid substituted on neisserial
lacto-N-neotetraose (LNnT) LOS may function similarly to sialic acid on host cells and
assist in subverting the AP by enhancing interactions with FH. N. gonorrhoeae has
homologs of meningococcal fHbp and NspA. The gonococcal fHbp homolog, desig-
nated Ghfp (43), lacks a signal peptide, is not surface expressed, and does not
contribute to FH binding (43). Gonococcal NspA (N. gonorrhoeae NspA [Ng-NspA])
shares 95% identity with N. meningitidis NspA (Nm-NspA), but the role of Ng-NspA in
binding to FH and evasion of complement-mediated killing has not been investigated.
We sought to determine the role of Ng-NspA in complement evasion and serum
resistance and to compare the FH binding properties of Ng- and Nm-NspA.
Because of the importance of regulating the AP, the repertoire of FH ligands in
Neisseria species, and the observation that some gonococcal strains bound FH in the
absence of LOS sialylation, we sought to identify and characterize additional mecha-
nisms of FH binding and AP regulation in gonococci. A prominent role for Ng-NspA in
complement evasion is presented.
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RESULTS
Gonococcal NspA mediates binding to FH and FHL-1 through FH SCRs 6 and 7
independently of LOS sialylation. N. meningitidis binds FH SCRs 6 and 7 through
interactions with PorB, fHbp, and NspA (32–34, 40). We used the unsialylated “serum-
resistant” strain N. gonorrhoeae 15253, which has caused disseminated infection (44),
expresses PorB.1A, and binds more FH than PorB.1B isolates but does not express LNnT
LOS (expresses only lactose from both heptose I [HepI] [similar to the “2-Hex HepI LOS”
expressed by ΔlgtA mutants described below] and HepII). N. gonorrhoeae 15253 binds
FH as reported previously (37) and also binds FHL-1 (Fig. 1, left and middle panels, blue
histograms). N. gonorrhoeae 15253 NspA and meningococcal NspA share 95% iden-
tity at the amino acid level (Fig. 5 shows sequence alignments). To determine if NspA
was involved in FH/FHL-1 binding to wild-type N. gonorrhoeae 15253 (15253 wt), we
examined the binding of FH and FHL-1 to an nspA deletion mutant (Fig. 1, left and
middle panels, red histograms). Deletion of nspA decreased binding of FH and FHL-1 to
N. gonorrhoeae 15253 ΔNspA by 2.6- and 3.1-fold, respectively, compared to N. gonor-
rhoeae 15253 wt. Similar to Nm-NspA, we determined that strain 15253 also bound FH
and FHL-1 specifically through domains 6 and 7 by showing that a fusion protein
comprising FH SCRs 6 and 7 fused to Fc (FH SCR6-7/Fc) (Fc was used as a target for
detection) bound to N. gonorrhoeae 15253 wt but only minimally to N. gonorrhoeae
15253 ΔNspA (Fig. 1, right panel). Figure S1 in the supplemental material shows
cumulative data from all experiments.
N. gonorrhoeae has a homolog of meningococcal fHbp, named Ghfp, that lacks a
signal peptide, is not expressed on the gonococcal surface, and does not bind FH (43).
Inactivation of ghfp in strain 15253 did not affect the ability of 15253 to bind FH or to
resist killing by normal human serum (NHS) (data not shown), and we concluded that
Ghfp was not involved in binding to FH or serum resistance in strain 15253.
LOS glycans impact FH binding to NspA. To extend the results observed with N.
gonorrhoeae 15253 to other N. gonorrhoeae strains, we next examined N. gonorrhoeae
strains UU1 and FA1090 for their ability to bind to FH and FHL-1. In contrast to 15253,
wild-type unsialylated N. gonorrhoeae strains UU1 and FA1090 bound FH and FHL-1
only weakly (Fig. 2A, histograms depicted by broken green lines). Both UU1 and FA1090
express the extended LNnT LOS from HepI (“4-Hex HepI LOS”), as determined by
binding of monoclonal antibody (mAb) 3F11 (data not shown) that recognizes the
terminal lactosamine structure of LNnT (45). We previously showed that the length of
HepI glycan extensions affects FH binding to NspA expressed on N. meningitidis;
mutants that expressed lactose from HepI bound more FH through NspA than LNnT-
expressing parent strains (33). Notably, N. gonorrhoeae 15253 harbors a natural defect
in lgtB that results in the expression of lactose (2-Hex HepI) LOS, while both UU1 and
FA1090 express the longer LNnT LOS (4-Hex HepI) species. We hypothesized that the
FIG 1 Gonococcal NspA mediates binding to FH and FHL-1 through FH domains 6 and 7. Shown are data
for binding of human FH (10 g/ml) (left panel), recombinant human FHL-1 (10 g/ml) (middle panel),
and FH SCR6-7/Fc (5 g/ml) (right panel) to gonococcal strain 15253 by flow cytometry. Binding to the
wild-type strain is shown with a blue line, binding to the ΔNspA mutant is shown with a red line, and
conjugate controls (bacteria plus fluorescent conjugate) with a gray shaded histogram. Numbers
alongside the histograms represent the median fluorescence values of the entire bacterial population.
The x axis shows fluorescence (log10 scale); the y axis shows counts. Figure S1 in the supplemental
material shows cumulative data from all experiments.
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shorter HepI glycan extension (lactose) from 15253 HepI would pose less hindrance for
FH and FHL-1 binding to NspA than LNnT expressed from HepI of UU1 and FA1090. To
determine if truncation of HepI LOS facilitated binding of FH and FHL-1 to NspA, we
inactivated lgtA, which results in the shortening of 4-Hex HepI LOS (LNnT) to lactose
extending from HepI of N. gonorrhoeae FA1090 and UU1, and assessed the role of FH
and FHL-1 binding to NspA. Similar to 15253, binding of FH and FHL-1 to lgtA-null
mutants of FA1090 and UU1 was readily detected by fluorescence-activated cell sorter
(FACS) analysis (Fig. 2A). As described above for 15253 (Fig. 1B), this binding was also
dependent upon the expression of NspA and involved binding to FH/FHL-1 SCRs 6 and
7 (Fig. 2B). These data provide evidence, for the first time, that gonococcal NspA plays
a role in binding of FH and FHL-1 to N. gonorrhoeae in the absence of LOS sialylation.
Figure S2 in the supplemental material shows cumulative data from all experiments.
LOS sialylation impedes binding of FH domains 6 and 7 to Ng-NspA.We sought
to determine whether sialylation of gonococcal LNnT LOS affected binding of FH
domains 6 and 7 to Ng-NspA. Contrary to findings in N. meningitidis, where FH binding
to Nm-NspA is enhanced by sialylation of LNnT LOS (33), sialylation of N. gonorrhoeae
LNnT LOS impeded binding of FH SCR6-7/Fc to NspA (Fig. 3, top left graph). Deletion
of nspA resulted in a loss of binding of FH SCR6-7/Fc to unsialylated strain FA1090 (Fig.
2B, bottom panel, and Fig. 3, bottom left panel). Sialylation of gonococcal LNnT LOS
enhances binding of FH SCRs 18 to 20 to N. gonorrhoeae (41) and was used as a positive
control (Fig. 3, top right graph). Deletion of NspA did not diminish binding of full-length
FH to N. gonorrhoeae PorB in bacteria with sialylated LOS (data not shown) and in a
corresponding fashion did not affect binding of FH SCR18-20/Fc (Fig. 3, bottom right
FIG 2 Truncation of heptose I (HepI) glycan extensions increases binding of FH and FHL-1 to N.
gonorrhoeae. (A) Binding of human FH (10 g/ml) and recombinant human FHL-1 (10 g/ml) to gono-
coccal PorB.1A strain UU1 and PorB.1B strain FA1090 was measured by flow cytometry. Binding was
compared in wild-type strains that express 4 hexose residues (LNnT) (“4 Hex HepI LOS”) from HepI LOS
(green line), isogenic ΔlgtA mutant strains that express truncated LOS with only 2 hexose residues
(Gal-Glc) from HepI (blue line) (“2 Hex HepI”), and isogenic mutant strains that lack both lgtA and NspA
(red line) ΔlgtA ΔNspA). (B) Binding of FH domains 6 and 7 to ΔlgtA mutants occurs through NspA.
Binding of FH SCR6-7/Fc (5 g/ml) to ΔlgtA (blue line) (2 Hex Hep I LOS) and ΔlgtA ΔNspA (red line)
isogenic mutants of N. gonorrhoeae UU1 and FA1090 was measured by flow cytometry. Numbers
alongside histograms and axes are as described above for panel A. The result for one experiment that
is representative of data from at least two independent experiments is shown. Figure S2 in the
supplemental material shows cumulative data for all experiments.
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graph). Deletion of NspA abrogated binding of FH, FHL-1 (Fig. 2A), and FH SCR6-7/Fc
(Fig. 2B) to unsialylated FA1090 and binding of FH SCR6-7/Fc to sialylated FA1090
(Fig. 3, bottom left graph). These findings show that sialylation of gonococcal LNnT LOS
enhances binding of FH SCRs 18 to 20 to N. gonorrhoeae (37, 42) but diminishes binding
of FH SCRs 6 and 7 to Ng-NspA. Figure S3 in the supplemental material shows
cumulative data from all experiments.
Histidine residues in human SCR6 are important for FH binding to Ng-NspA.
Binding of FH to Ng- and to Nm-NspA (and also to N. meningitidis fHbp) is human
specific (32, 33, 40, 46, 47). To determine if histidine (His) residues at positions 337, 360,
and 371 in human FH SCR6, shown previously to be important in N. meningitidis fHbp
binding (40, 47), were also important for binding of Ng-NspA to FH SCR6, we used a
series of FH SCR5-8/Fc mutant proteins in which each of three His residues in human
FH SCR6 were mutated to mirror the corresponding amino acid sequences present in
the rhesus macaque counterpart of FH SCR6 (H337Y, H360P, and H371Y), either
individually or in combination (40). Binding of FH to both Nm-NspA and Ng-NspA is
human specific; rhesus FH5-8/Fc did not bind to NspA from either neisserial species
(data not shown).
Flow cytometry was used to measure binding of FH SCR5-8/Fc and the seven His
mutant derivatives of FH SCR5-8/Fc to N. gonorrhoeae strains 15253, UU1, and FA1090
FIG 3 Sialylation of lacto-N-neotetraose (LNnT) LOS decreases binding of FH SCR6-7/Fc to gonococci expressing NspA.
Binding of FH SCR6-7/Fc (5 g/ml) or FH SCR18-20/Fc (5 g/ml) to wild-type gonococcal strain FA1090 (top panel) and
its isogenic nspA deletion mutant (bottom panel) grown either with (shaded histograms) or without (solid lines)
CMP-Neu5Ac (25 g/ml) added to the growth medium was measured by flow cytometry. Negative-control reactions (no
FH fusion protein added) are shown by shaded gray histograms. In all graphs, the x axis represents fluorescence intensity
on a log10 scale, and the y axis represents the number of events; numbers are the median fluorescence values of FH
SCR/Fc binding to the entire bacterial population. Data from one experiment that are representative of results from at
least three independent experiments are shown. Figure S3 in the supplemental material shows cumulative data from two
separate experiments.
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and to an unencapsulated N. meningitidis mutant strain, A2594 ΔfHbp (32), devoid of
fHbp expression (Fig. 4A). All three N. gonorrhoeae strains and the N. meningitidis strain
bound FH in a manner analogous to that for fHbp protein variants 2 and 3 (subfamily
A) (40), where mutation of H337 alone or in combination with either H360 or H371 had
resulted in decreased binding of SCR5-8. Mutations in H360 or H371 alone and in
combination increased binding compared to the unmutated FH SCR5-8/Fc protein (Fig.
4A). The specificity of these findings using intact N. gonorrhoeae were also determined
by an enzyme-linked immunosorbent assay (ELISA) using Escherichia coli microvesicles
(MVs) that expressed gonococcal NspA from strains 15253, UU1, and FA1090 (Fig. 4B).
Similar to whole N. gonorrhoeae strains, mutations in H337 alone or in combination with
either H360P or H371Y diminished binding of FH SCR5-8/Fc to all three Ng-NspA-
FIG 4 Role of human FH SCR6 histidine residues 337, 360, and 371 in binding of FH to gonococcal and
meningococcal NspAs. (A) Binding of human FH SCR5-8/Fc with wild-type SCR6 (labeled “5-8”) and
human FH SCR5-8/Fc with point mutations in histidine (His) residues 337, 360, and 371 in SCR6 (“triple”
indicates that all 3 His residues have been changed, collectively referred to as FH/Fc below) to
gonococcal strain 15253 (solid gray bars), the 2-Hex HepI LOS mutants of UU1 (striped bars) and FA1090
(white bars), and N. meningitidis strain A2594 ΔfHbp (solid black bars) measured by FACS analysis. The
y axis represents the corrected median fluorescence of FH/Fc binding to the entire bacterial population,
where binding of FH/Fc to isogenic mutant strains lacking NspA was subtracted from binding to the
wild-type strain to represent net (corrected) NspA-specific binding. Each bar represents the mean
(range) of data from two independent experiments. Comparison of binding of the different FH/Fc
molecules to each strain was performed by one-way ANOVA (P 0.0001 for all three strains), and
pairwise comparisons of binding of each FH/Fc molecule with binding to FH SCR5-8/Fc on that strain
were made using Dunnett’s multiple-comparison test (*, P 0.05; **, P 0.01; ***, P 0.001; ****,
P 0.0001). (B) Binding, measured by ELISAs, of FH SCR5-8/Fc and seven His mutants in SCR6 to E.
coli membrane vesicles (MVs) expressing NspA from gonococcal strains 15253 (grey bars), UU1
(striped bars), and FA1090 (white bars). Negative controls included microtiter wells in which the
FH/Fc fusion protein was omitted, a well that contained FH18-20/Fc (labeled “18-20”), and wells
coated with MVs prepared from strains harboring the vector alone (vector control; no gonococcal
NspA). Values from the “vector control” wells were subtracted as background binding. The y axis
shows the absorbance (optical density [OD]) at 405 nm. Each bar represents the mean (range) of data
from 3 independent experiments. Comparison of binding of the different FH/Fc molecules to each
strain was performed by one-way ANOVA (P 0.0001 for all three strains). Pairwise comparisons
between the binding of each FH/Fc molecule with binding to FH SCR5-8/Fc on that strain were
performed using the Holm-Sidak multiple-t-test method, and the adjusted P values are indicated (*,
P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001).
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containing vesicles. As reported previously using N. meningitidis that displayed variant
1 fHbp (40), mutating H337 in conjunction with H371 had the greatest effect. Together,
these data highlight that Ng-NspA shares a binding mechanism with Nm-NspA and N.
meningitidis fHbp; H337 and H371, two of the three histidine residues in SCR6 that are
important for binding to polyanions, also participate in interactions between FH SCR6
and neisserial pathogens.
Enhanced binding of FH and FHL-1 to Nm-NspA relative to Ng-NspA is medi-
ated via V112 and D113 in surface loop 3. Binding of full-length FH to E. coli MVs
harboring Ng-NspA molecules from N. gonorrhoeae strains 15253, UU1, and FA1090 was
compared to binding to MVs containing Nm-NspA. Dose-dependent binding of FH to
Nm-NspA in MVs was readily detected, consistent with data from previous reports (33).
Unexpectedly, full-length FH did not bind to Ng-NspA expressed in E. coli MVs (Fig. 5).
This result was surprising because all three N. gonorrhoeae strains bound FH, FHL-1, FH
SCR5-8/Fc, and FH SCR6-7/Fc in an NspA-dependent manner (Fig. 1 to 3), and E. coliMVs
expressing Ng-NspA bound to FH SCR5-8/Fc (Fig. 4B). Ng-NspAs in MVs each showed
equivalent amounts of expression compared to Nm-NspA in Coomassie blue-stained
FIG 5 Comparison of FH binding to and sequences of meningococcal and gonococcal NspAs. (A) Binding of
full-length human FH to recombinant meningococcal NspA 8047 (87) or gonococcal (strains UU1, 15253, and
FA1090) NspAs expressed in E. coli MVs was compared by ELISA. Negative controls included ELISA measure-
ments where FH was omitted and reactions that used MVs prepared from strains harboring the vector alone
(vector control; no gonococcal NspA). Vector control optical density at 405 nm readings were considered the
background and subtracted. FH concentrations are shown on the x axis, and absorbances at 405 nm are shown
on the y axis. Data from a single experiment are shown, which are representative of results from at least 3
independent and reproducible experiments performed. (B) Comparison of the predicted amino acid se-
quences of NspAs from N. gonorrhoeae strains UU1, 15253, F62, 252, FA1090, and FA19. The predicted signal
peptide (black line), surface-exposed loops (black boxes) (loops 1 to 4), and beta sheets (blue arrows) are
indicated (48). Amino acids in the gonococcal NspAs that differed from meningococcal NspA are shaded, and
the corresponding amino acid found in the meningococcal NspA is shown above the alignment in red font.
NspA and Complement Resistance Infection and Immunity
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gels (data not shown); thus, different amounts of NspA did not explain the lack of
binding. In the gonococcal background, binding of FH to NspA was observed best
when the LOS HepI chain was truncated, and we surmised that the E. coli background
was not optimal for Ng-NspA interactions with full-length FH. Binding of FH SCR5-8/Fc
to Ng-NspA in E. coli MVs may have been facilitated by fewer steric constraints with the
FH5-8 fragment than with intact FH. Consistent with this, we found that Ng-NspA
expressed in a heterologous meningococcal background bound less FH than a heter-
ologous Nm-NspA protein expressed in the same background (see Fig. S4 in the
supplemental material).
Based on the results in Fig. 5A, we speculated that Nm-NspA has a higher affinity for
FH and FHL-1 than Ng-NspA. We compared the predicted amino acid sequences of
NspAs from six gonococcal strains (15253, UU1, FA1090, 252, FA19, and F62) to those
of meningococcal NspA sequences deposited in GenBank (Fig. 5B). Overall, NspA was
highly conserved; gonococcal NspA proteins shared97% identity with each other and
at least 94% identity with meningococcal NspA (Fig. 5B). The NspA sequences from N.
gonorrhoeae strains UU1 and 252 were identical, as were those from 15253 and F62.
The crystal structure of Nm-NspA indicates that the protein is an eight-stranded
antiparallel beta-barrel with four short surface-exposed loops (48). Based on the crystal
structure, we focused on divergent amino acids located in the surface-exposed loops of
NspA (Fig. 5B) that were anticipated to interact with FH. The amino acid at position 157
of Nm-NspA was variable and predicted to be in loop 4; however, this residue was not
further investigated because two of four of our gonococcal sequences (15253 and
FA19) contained the same amino acid (T) as the one in meningococci; therefore, this
residue was unlikely play a role in differential binding of FH. Three amino acids, two in
loop 3 and one in loop 2, were targeted. Loop 3 was of particular interest because it is
important for the binding of the protective anti-Nm-NspA mAbs AL12 and 14C7 (49).
Ng-NspA was found to contain Ala (A) and His (H) exclusively at positions 112 and 113
in loop 3, while Nm-NspA encodes Val (V) and Asp (D) exclusively at positions 112 and
113. Position 73 in loop 2 of NspA from UU1, 15253, and FA1090 is occupied by a Gln
(Q) residue that is absent from N. gonorrhoeae FA19 and all of the Nm-NspA sequences
available in GenBank. Loop 2 may also play a role in the binding of protective mAbs,
and the role of this Q residue in FH binding was also investigated.
Site-directed mutagenesis (SDM) was used to create Nm-NspA to Ng-NspA, and,
conversely, Ng-NspA to Nm-NspA, exchanges at position 73 (loop 2) alone, positions
112 and 113 (loop 3) together, or positions 73, 112, and 113 simultaneously. Analysis of
FH and FHL-1 binding to wild-type and SDM-mutated NspA proteins expressed in MVs
indicated that V112 and D113 in surface loop 3 of Nm-NspA were important for enhanced
binding of FH and FHL-1 to Nm-NspA relative to Ng-NspA; mutation of these Nm-NspA
amino acids to their Ng-NspA counterparts (A112 and H113, respectively) decreased
binding of both complement inhibitors (Fig. 6A). Introduction of Gln (Q) at position 73
of Nm-NspA decreased binding of FH but not FHL-1. The triple Nm-NspA to Ng-NspA
mutant reduced binding of FH and FHL-1 to levels seen with Ng-NspA. Conversely,
deletion of Q73 in Ng-NspA increased binding of FH and FHL-1 to levels that were
30% of those seen with Nm-NspA (Fig. 6B). N. gonorrhoeae to N. meningitidis
mutations in NspA at positions 112 and 113 enhanced FH and FHL-1 binding to
60% and 100% of the levels seen with Nm-NspA. While the triple N. gonorrhoeae
to N. meningitidis mutations in Ng-NspA restored binding of FH to levels seen with
Nm-NspA, binding to FHL-1 was only 30% of that seen with Nm-NspA (Fig. 6B).
Anti-Nm-NspA mAb Me-7 binds to loop 3 (49). MVs harboring mutated Nm-NspA
encoding A113 and H114 also lost the ability to react with this mAb (data not shown). We
previously showed that Me-7 blocked FH binding to N. meningitidis, which further
supports the importance of loop 3 in interactions with FH.
Collectively, these data show that the amino acids at positions 73, 112, and 113 are
important for FH and FHL-1 binding. FHL-1 binds better to NspA than FH, likely because
of less steric hindrance for domains 6 and 7 in FHL-1 imposed by the 13 additional
C-terminal domains of full-length FH. However, there are differences in how FH and
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FHL-1 interact with NspA; as an example, the triple N. gonorrhoeae to N. meningitidis
NspA mutation fully restores binding of FH to levels seen with Nm-NspA but permits
FHL-1 binding to only 30% of the levels seen with Nm-NspA.
Expression of Ng-NspA enhances serum resistance. FH downregulates the alter-
native pathway of complement; therefore, bacteria that bind FH are predicted to be
more resistant to complement-mediated serum killing than those that do not bind FH.
The role of Ng-NspA in serum resistance was assessed with a serum bactericidal assay
with NHS to compare serum resistance of N. gonorrhoeae strains UU1 and FA1090 and
their isogenic NspA mutants (Fig. 7). Loss of NspA from N. gonorrhoeae strains UU1 and
FA1090 and their isogenic lgtA mutants resulted in significantly increased sensitivity to
killing by NHS (Fig. 7). FA1090 is intrinsically more serum resistant than UU1 by virtue
of its ability to bind C4b binding protein (C4BP) (50); therefore, higher concentrations
of NHS were required to achieve killing and reveal the role of NspA in serum resistance.
Overall, these data support a role for NspA in gonococcal complement evasion.
DISCUSSION
In this study, we have identified a key role for Ng-NspA in binding FH and comple-
ment evasion. As previously described for Nm-NspA (33), Ng-NspA binds FH and FHL-1
FIG 6 Amino acids in loops 2 and 3 modulate binding of FH and FHL-1 to NspA. (A) Binding of FH (left graph) and
FHL-1 (right graph) to E. coli MVs prepared from E. coli expressing recombinant wild-type meningococcal NspA
(solid black squares) or meningococcal NspA bearing N. meningitidis-to-N. gonorrhoeae mutations, measured by
ELISAs. The mutant meningococcal NspA molecules included (i) addition of Q at position 73 (Q73) (solid red
triangles); (ii) V-to-A and D-to-H mutations at positions 112 and 113, respectively (VD¡AH) (inverted open blue
triangles); or (iii) a combinedQ73,VD¡AH mutation (filled green diamonds). E. coliMVs expressing Ng-NspA were
included as a comparator (filled gray circles). x axis, concentration of FH or FHL-1; y axis, absorbance at 405 nm
(optical density [OD] at 405 nm). (B) Binding of FH (left graph) and FHL-1 (right graph) to Ng-NspA expressed in E.
coli MVs, measured by ELISAs. Gonococcal NspA was modified by (i) deleting Q at position 73 (Q73) (open red
triangles); (ii) making A-to-V and H-to-D mutations at positions 112 and 113, respectively (AH¡VD) (solid blue
inverted triangles); and (iii) a combined Q73 and AH¡VD triple mutation (open green diamonds). Nm-NspA-
containing MVs (solid black squares) were included for comparison. Axes are as described above for panel A.
Two-way ANOVA was used to compare binding of FH/FHL-1 to wild-type Nm-NspA with binding to Ng-NspA and
the other mutant NspA molecules. In each instance, there was a statistically significant interaction between
concentration and binding (P 0.0001). Dunnett’s multiple-comparison test was used to compare binding of
FH/FHL-1 to Nm-NspA with binding to each of the other NspA molecules; significance was set at a P value of 0.05.
In the top left graph, Nm-NspA bound significantly more (P 0.05) FH than each of the other molecules at all
concentrations of 2.5 g/ml. In the top right graph, Nm-NspA bound significantly more FHL-1 than each of the
other NspA molecules at all concentrations tested (i.e., 0.125 g/ml). In the bottom left graph, Nm-NspA bound
significantly more FH than (i) Ng-NspA at all concentrations tested (i.e., 1.25 g/ml), (ii) Ng-NspA Q73 at a
concentration of 2.5 g/ml and Ng-NspA AH¡VD, and (iii) Ng-NspA Q73 AH¡VD at 5 and 10 g/ml. In the
bottom right graph, Nm-NspA bound significantly more FHL-1 than all the tested NspA mutants, except Ng-NspA
AH¡VD, at all concentrations of 0.25 g/ml.
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through SCR domains 6 and 7. We have identified NspA loops 2 and 3 as being
important for interactions with FH and FHL-1 and elucidated differences in how FH
interacts with Ng- and Nm-NspA. Similar to our findings with N. meningitidis (33),
truncation of LOS glycan extensions from HepI increases binding of FH to Ng-NspA. As
also noted previously with N. meningitidis (32), Ng-NspA functions to increase comple-
ment resistance on N. gonorrhoeae when HepI expresses LNnT LOS, despite low levels
of FH binding detected by flow cytometry. Differences in the amounts of FH/FHL-1
bound by Ng- and Nm-NspA may be attributed to differences in amino acids at
positions 72 (loop 2), 112 (loop 3), and 113 (loop 3); the presence of Q72, A112, and H113,
as seen in most N. gonorrhoeae strains, decreases binding, while deletion (or absence)
of Q at position 72 and the presence of V and D at positions 112 and 113, respectively,
as seen in N. meningitidis, all increase FH/FHL-1 binding. In addition to the differences
in affinities for FH, another noteworthy difference between the interactions of NspA on
N. gonorrhoeae and N. meningitidis is the effect of LOS sialylation; while sialylation of N.
meningitidis lacto-N-neotetraose (LNT) LOS enhances FH binding to NspA (33), the
opposite is seen with N. gonorrhoeae. The reason for this difference is unclear, but a
difference in the exposure of NspA in the presence of LOS sialylation is a possible
explanation. However, the decrease in binding of FH domains 6 and 7 to Ng-NspA seen
with N. gonorrhoeae LOS sialylation is offset by an increase in FH binding through
domains 18 through 20. This dual mechanism of engaging human FH may permit the
bacterium to evade complement while varying the LOS glycan composition, as dis-
cussed below.
The high incidence of invasive meningococcal disease and disseminated gonococcal
infection (DGI) in persons deficient in terminal complement components (51–54)
underscores the importance of complement in host defenses against these infections.
Both N. gonorrhoeae and N. meningitidis have developed several mechanisms to escape
killing by complement, including binding of complement inhibitors such as FH and C4b
binding protein (C4BP) (35, 37, 38, 42, 50, 55, 56, 57, 59). Sialylation of LNT LOS of N.
gonorrhoeae enhances binding of FH through its C terminus (domains 18 through 20)
(36, 37, 41). LNT sialylation is important for establishing experimental urethral infection
in men (60–62) and also in the mouse vaginal colonization model of gonorrhea (63, 64).
FIG 7 Expression of NspA enhances survival in normal human serum. Shown is survival in normal
human serum (NHS) of gonococcal strains UU1 (A) and FA1090 (B) expressing either 4-Hex HepI LOS
(LNnT) (wild-type strain, solid black bars) or 2-Hex HepI LOS (ΔlgtA mutant, solid gray bars) and their
isogenic NspA mutants (black or gray striped bars, respectively). The percentage of NHS used is
indicated on the x axis. The percent survival after incubation in serum at 30 min relative to CFU
counts at time zero is plotted on the y axis (means [standard errors of the means {SEM}] of data from
3 independent experiments). Each bar represents the SEM of results from 3 independent observa-
tions. Pairwise comparisons were made using the t test. **, P 0.01; ***, P 0.001; ****, P 0.0001
(2-way ANOVA).
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The organism likely needs to finely balance the level of LOS sialylation. Excessive LOS
sialylation may impede gonococcal colonization of men (61) because unsialylated LNT
is required for binding to the asialoglycoprotein receptor (ASGP-R) to gain entry into
male urethral epithelial cells (65). Phase variation of LOS may also enable the bacteria
to evade anti-LOS immune responses (66). N. gonorrhoeae strains often express multiple
LOS structures simultaneously (67, 68). A recent survey of 75 minimally passaged N.
gonorrhoeae isolates obtained from men who attended a sexually transmitted
diseases clinic in Nanjing, China, revealed that 100% of isolates expressed LNnT but
also simultaneously expressed LOS with only lactose extensions from HepI, evi-
denced by reactivity with mAb 2-1-L8 (69–71). The ability to retain FH binding even
in the absence of LNnT sialyation, in this instance by binding of FH SCR domains 6
and 7 by NspA, will enable complement evasion. It is worth emphasizing that while
binding of FH and FHL-1 increases with HepI glycan truncation (i.e., when lgtA is
phase varied “off”), NspA enhances serum resistance, even in wild-type isolates that
also express LNnT LOS.
Meningococcal NspA was evaluated as a vaccine candidate, but those studies did
not predict protection (72). Several reasons could have contributed to the predicted
nonefficacy of the vaccine preparation. First, the recombinant protein that was pro-
duced in E. coli may not have folded properly and therefore may not have presented
the same epitopes seen on native organisms. Second, binding of human FH to NspA
may have reduced immunogenicity to the surface-exposed FH binding regions of NspA,
which may also be targets for bactericidal antibodies such as Me-7. A similar phenom-
enon occurs when humans or mice that express human FH (human FH transgenic mice)
are immunized with fHbp. Binding of human FH to N. meningitidis fHbp diverts the
immune response to regions of the molecule that do not bind to FH (73–75). The
elicited antibodies do not prevent FH from binding to bacteria, and the bacterium-
bound FH dampens the bactericidal activity of vaccine antibodies. Amino acid muta-
tions in fHbp that maintain the overall structure and immunogenicity, but which
eliminate binding of human FH, elicit antibodies that divert FH away from the bacterial
surface and are more bactericidal than antibodies that do not block FH binding (74).
This study has identified the amino acids that modulate FH binding to NspA and could
guide the rational design of neisserial NspA-based vaccines.
The worldwide emergence of multidrug-resistant gonococcal strains necessitates
the development of novel treatments and immunotherapeutics against N. gonorrhoeae.
An approach that our group has used to combat drug-resistant bacteria is to fuse the
microbial binding domains of human FH to IgG Fc (39). The resulting fusion protein acts
by blocking binding of FH to the microbial surface, while the Fc domain activates
complement, which in turn can result in the insertion of lytic membrane attack
complexes to kill Gram-negative bacteria or engage Fc receptors and complement
receptors for C3 fragments on phagocytes. We have demonstrated the efficacy of a
chimeric protein where FH domains 18 through 20 are fused to Fc against N. gonor-
rhoeae (39, 41, 76). Based on the finding that N. gonorrhoeae also binds FH domains 6
and 7, we have fused these two domains with human IgG1 Fc to create FH SCR6-7/Fc.
Ongoing work has shown that FH SCR6-7/Fc is effective against N. gonorrhoeae both in
vitro and in vivo (77, 78). We speculate that the use of FH SCR18-20/Fc and FH SCR6-7/Fc
may provide additive or synergistic activity because these molecules bind to distinct
targets on the bacterial membrane. Furthermore, their use in combination will also raise
the barrier to the development of resistance.
In conclusion, we have defined NspA as a ligand for human FH and FHL-1 and an
important factor that contributes to gonococcal complement resistance. Elucidating
the molecular basis for the interaction between FH domains 6 and 7 and NspA will
prove useful in informing the development of novel vaccines and therapeutics against
multidrug-resistant gonorrhea that has emerged as a global threat to human health
worldwide.
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MATERIALS AND METHODS
Ethics statement. This study was approved by the Committee for the Protection of Human Subjects
in Research at the University of Massachusetts Medical School. All subjects who donated blood for this
study provided written informed consent.
Bacterial strains, bacterial growth conditions, and mutagenesis. N. gonorrhoeae PorB.1A strains
UU1 (79, 80) and 15253 (81) and PorB.1B strain FA1090 (82) have all been described previously. N.
meningitidis A2594 (also called WUE2594) is a serogroup A strain that expresses high levels of NspA (83);
inactivation of mynB (to abrogate expression of capsule), fHbp, and nspA in A2594 was described
previously (33). N. gonorrhoeae and N. meningitidis were routinely grown on chocolate agar plates
supplemented with an IsoVitaleX equivalent at 37°C in an atmosphere enriched with 5% CO2. GC plates
supplemented with the IsoVitaleX equivalent were used for antibiotic selection. DNA transformation of
N. gonorrhoeae was performed as described previously (84). The following antibiotics were used when
indicated; 100 g/ml kanamycin, 50 g/ml spectinomycin, 2 g/ml erythromycin, and 10 mg/ml strep-
tomycin. Escherichia coli strains (Invitrogen, Carlsbad, CA) were routinely cultured in Luria-Bertani (LB)
broth or on LB agar. The following antibiotics were used as needed: 50 g/ml kanamycin, 150 g/ml
ampicillin, 400 g/ml erythromycin, and 100 g/ml spectinomycin. Sialylation of LOS was achieved by
growing bacteria in gonococcal liquid medium supplemented with cytidine-5=-monophospho-N-
acetylneuraminic acid (CMP-Neu5Ac) (25 g/ml).
Insertional inactivation of nspA in N. meningitidis has been described previously (33). A linearized
plasmid harboring the meningococcal nspA gene with a 130-bp deletion and a spectinomycin resistance
cassette was used to transform N. gonorrhoeae. NspA deletion mutants were similarly constructed in N.
gonorrhoeae strains UU1, 15253, and FA1090. PCR was used to confirm the nspA::spc genotype, and
Western blotting with anti-NspA mAb Me-7 (kindly provided by Dan Granoff, CHORI, Oakland, CA) was
used to confirm the loss of NspA. Insertional inactivation of lgtA was accomplished as described
previously (33, 85), using a plasmid harboring lgtA::kan. Insertional inactivation of lgtA was confirmed by
PCR, and truncation of LOS was evidenced by migration on SDS-PAGE gels following staining with silver
and by loss of reactivity with mAb 3F11 in Western blot assays.
DNA sequencing. The nspA gene was amplified by PCR from N. gonorrhoeae strains UU1, 15253,
FA1090, FA19, and F62, and the PCR product was directly sequenced. Sanger DNA sequencing of all PCR
products and plasmid constructs was performed by GeneWiz (Cambridge, MA). Predicted amino acid
sequences were compared using ClustalW (http://www.genome.jp/tools-bin/clustalw).
Sera. Serum collected from healthy human volunteers without a history of neisserial disease was
aliquoted and stored at 80°C until needed. Hemolytic activity of the serum was confirmed using a total
hemolytic complement assay (Binding Site, Birmingham, UK). Complement activity in the sera was
inactivated, when necessary, by heating at 56°C for 30 min. The sera used did not contain NspA-specific
antibodies as revealed by Western blotting of whole bacterial lysates that were probed with serum.
Expression of NspA in E. coli and preparation of microvesicles. E. coli BL21(DE3) (Invitrogen,
Carlsbad, CA) harboring recombinant N. meningitidis nspA from N. meningitidis strain 8047 on plasmid
pGMS 1.0 was described previously (49, 86). Gonococcal nspA genes were amplified from N. gonorrhoeae
strains UU1, 15253, and FA1090 (primers NspABamH1_F and NspAHindIII_R [see Table S1 in the
supplemental material]), cloned into pBluescript II SK (Stratagene, La Jolla, CA), digested with BamHI
and HindIII, and transformed into E. coli BL21(DE3). The resulting clones, harboring plasmids pGMS_UU1,
pGMS_15253, and pGMS_FA1090, were verified by DNA sequencing.
E. coli BL21(DE3) harboring recombinant nspA on plasmid pGMS 1.0, pGMS_UU1, pGMS_15253, or
pGMS_FA1090 or E. coli harboring the pBluescript II SK vector alone was used to prepare microvesicles
(MVs) as previously described (49, 86). MV preparations were quantified by a bicinchoninic acid (BCA)
protein assay and visualized on 12% Bis-Tris polyacrylamide gels (Invitrogen, Carlsbad, CA) stained with
Coomassie blue and by Western blotting with anti-NspA mAb Me-7.
Site-directed mutagenesis of nspA. Site-directed mutagenesis (SDM) of nspA was used to alter
specific amino acids in Nm- and Ng-NspA, and the wild-type and mutated NspA proteins were expressed
in E. coli and isolated as MVs. Based on the sequence dissimilarity between Nm-NspA and Ng-NspA (Fig.
4), the following point mutations were constructed: insertion of Q73 (Q73) in loop 2 and V112A and
D113H (VD¡AH) in loop 3 in Nm-NspA and deletion of Q73 (ΔQ73) and A112V and H113V (AH¡VD) in
Ng-NspA. Similarly, we created “double” mutants in both Nm-NspA (Q73,VD¡AH) and Ng-NspA
(ΔQ73,AH¡VD). Point mutations were created using the QuikChange II site-directed mutagenesis kit
according to the manufacturer’s instructions (Stratagene, La Jolla, CA). Primers (see Table S1 in the
supplemental material were designed using the QuikChange primer design program (Agilent Technol-
ogies). All constructs were validated by DNA sequencing.
Recombinant FH fragment/Fc fusion proteins. FH/mouse IgG2a Fc fusion constructs that contain
contiguous FH SCR domains (SCRs 5 to 8, SCRs 6 and 7, and SCRs 18 to 20) fused to the N terminus of
the Fc fragment of murine IgG2a (FH/Fc fusion proteins) and human FH SCR5-8/Fc constructs with point
mutations in His337, His360, and His 371 in SCR6 were described in detail previously (36, 40). These SCR
6His residues are surface exposed and have been shown to be important for binding of FH to
polyanions and to the meningococcal fHbp protein (27, 40). FH/Fc constructs were purified from culture
supernatants collected from transiently transfected Chinese hamster ovary (CHO) cells using protein
A/G-Sepharose (ThermoFisher, Waltham, MA) according to the manufacturer’s instructions. Purified FH/Fc
constructs were concentrated by centrifugation using an Amicon Ultra-30 centrifugal filter unit, and the
final protein concentration was determined by a BCA assay (Bio-Rad). Constructs were further assessed
by both Coomassie blue staining of proteins separated by lithium dodecyl sulfate (LDS)-PAGE and
Western blotting with both anti-FH polyclonal and anti-mouse IgG Fc antibodies. Goat anti-mouse IgG
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(Sigma-Aldrich, St. Louis, MO) was used to detect binding of recombinant FH/Fc fusion proteins to
bacteria; the use of the IgG Fc region for detection permits equal detection of each fusion molecule.
Flow cytometry. Flow cytometry to detect bound FH, recombinant FHL-1, or FH/Fc constructs was
performed as described previously (40). Briefly, bacteria were grown overnight on chocolate agar plates,
subcultured onto fresh chocolate agar, and grown at 37°C in 5% CO2. At 6 h, bacteria were washed with
Hanks’ balanced salt solution (HBSS) containing 1 mM CaCl2 and 1 mM MgCl2 (HBSS) and suspended
to a final concentration of 3 108 cells/ml; 107 organisms were centrifuged and incubated with either
FH purified from human plasma (Complement Technology, Inc., Tyler, TX) (concentration specified for
each experiment), recombinant FHL-1 (purified from CHO cell supernatants using a polyclonal anti-FH
affinity column as described above), or purified FH/Fc. Bound FH or FHL-1 was detected using either
affinity-isolated sheep anti-human FH (Lifespan Biosciences, Seattle, WA) or anti-FH mAb 90X (catalog no.
A254; Quidel, San Diego, CA). Fluorescein isothiocyanate (FITC)-conjugated anti-sheep IgG or anti-mouse
IgG (Sigma-Aldrich, St. Louis, MO) was used as a secondary antibody. While the polyclonal anti-FH
antibody provided higher sensitivity, relative differences in FH binding among strains using either of the
two reagents were similar. Bound FH/Fc constructs were detected using goat anti-mouse IgG-FITC
(Sigma-Aldrich, St. Louis, MO). All reactions were carried out in a solution containing HBSS–1% bovine
serum albumin (BSA). Flow cytometry was performed using a FACSCalibur instrument (Becton, Dickinson,
Franklin Lakes, NJ), and data analysis was performed using the FlowJo data analysis software package
(www.TreeStar.com). Reaction mixtures in which the primary ligand (FH, FHL-1, or FH/Fc) was omitted
served as negative controls.
Assessment of binding of FH, FHL-1, and FH/Fc constructs to NspA-containing E. coliMVs using
ELISAs. ELISAs were used to detect binding of FH, FHL-1, and FH/Fc constructs to NspA-containing
vesicles. Microtiter wells were coated with either NspA-containing or control MVs at a concentration of
10 g/ml in phosphate-buffered saline (PBS) overnight at 22°C. Nonspecific binding was blocked with
PBS–2.5% BSA for 2 h at 37°C. FH (concentrations ranging from 0 to 10 g/ml), FHL-1 (concentrations
ranging from 0 to 10 g/ml), or FH/Fc (5 g/ml) was added to wells for 1 h at 37°C, and bound ligand
was detected using polyclonal sheep anti-human FH followed by anti-sheep IgG conjugated with alkaline
phosphatase (for FH and FHL-1) or goat anti-mouse IgG conjugated with alkaline phosphatase (for FH/Fc
constructs), each for 1 h at 37°C.
Serum bactericidal assays. Bactericidal assays were used to compare serum resistances of wild-type
N. gonorrhoeae and nspA deletion mutants. Serum bactericidal assays have been described previously
(40, 87); the optimal concentration of serum was determined empirically for each strain. Bacteria from a
culture grown overnight on chocolate agar plates were inoculated onto fresh chocolate agar and allowed
to grow for 6 h at 37°C in 5% CO2. Briefly, 2,000 CFU of gonococci were incubated with serum
(concentrations specified for each experiment) in a final reaction mixture volume of 150 l. Aliquots of
25 l were plated in duplicate at the start of the assay (time zero [t0]) and after incubating the reaction
mixture at 37°C for 30 min (time 30 min [t30]). Survival was calculated as the number of viable colonies
at t30 relative to baseline colony counts at t0. Each experiment was repeated at least three times. The
average survival was calculated from at least three independent experiments, and error bars represent
the standard deviations. A t test was used to determine significance.
Statistics. Pairwise comparisons were made using the t test, and comparisons across groups were
made using analysis of variance (ANOVA) (GraphPad Prism 7.0).
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